Chee Kay Cheung, MBCHB, MRCP, PhD

Cheung comments on new and future IgAN treatment, and shares clinical pearls with other providers.

Cheung shares his approach to using novel immunotherapies in IgAN to prevent infection.

Cheung reviews the rationale for dual inhibition of BLyS and APRIL in IgAN, as well as the clinical impact of investigational agents on IgAN.

An expert nephrologist provides an overview of the pathophysiology of IgAN before discussing new immunomodulating therapies in clinical trials.

Chee Kay Cheung, MBCHB, MRCP, PhD, discusses unmet needs in the management of IgAN, commenting on the need for new medication and highlighting budesonide and SGLT2 inhibitors.

An expert nephrologist shares his opinion on newer treatments of IgAN such as budesonide and SGLT2 inhibitors, commenting that patients with greater disease progression stand to benefit the most from these treatments.

Chee Kay Cheung, MBCHB, MRCP, PhD, reviews newly approved agents for the treatment of IgAN, focusing on SGLT2 inhibitors, budesonide, and sparsentan.

Chee Kay Cheung, MBCHB, MRCP, PhD, comments on optimized supportive care for patients with IgAN, which monitors things like blood pressure, diet, and lifestyle.

Chee Kay Cheung, MBCHB, MRCP, PhD, reviews the disease burden and prevalence of immunoglobulin A nephropathy (IgAN), as well as risk factors for disease progression.